Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Luminex Corp (NASDAQ:LMNX)

Delayed Data
As of Feb 05
 -0.43 / -2.32%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. It operates its business through two segments: Technology & Strategic Partnerships, and Assays & Related Products. The Technology and Strategic Partnerships segment licenses the company's xMAP technology to its partners, who then develop products that incorporate the xMAP technology into products that they sell to end users. It also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells these products to its partners. The Assays and Related Products segment is primarily involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. This segment focuses on multiplexed applications for the human molecular clinical diagnostics market. Its products are focused on the three segments of the genetic testing market: Human Genetics, Personalized Medicine, and Infectious Disease. Luminex was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.

Contact Information

Luminex Corp.
12212 Technology Boulevard
Austin Texas 78727
P:(512) 219-8020
Investor Relations:
(512) 219-6325



Other institutional44.06%
Mutual fund holders35.41%
Individual stakeholders12.58%

Top Executives

Nachum ShamirPresident, Chief Executive Officer & Director
Harriss T. CurrieChief Financial Officer, Treasurer & SVP-Finance
Thomas J. CopaVice President-Technology & Strategic Partnerships
Charles J. CollinsVice President-Systems Research & Development
Richard W. RewSecretary, Senior Vice President & General Counsel